Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion

Degenerative Disc Disease Clinical Trial

Official title:

Prospective Evaluation of Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06000319
• Other study ID #: CT-NMP-001
• Status: Not yet recruiting
• Start date: September 2023
• Est. completion date: December 2025

Study information

• Verified date: August 2023
• Source: Induce Biologics USA Inc.
• Contact: Sean A Peel, Ph.D.
• Phone: 416-898-9724
• Email: sean.peel[@]redrockregen.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to evaluate the effectiveness and safety of Natural Matrix Protein™ (NMP™) fibers when used in cervical or lumbar interbody fusion in patients with degenerative disc disease (DDD), spinal stenosis, spondylolisthesis undergoing cervical or lumbar interbody spine fusion at no more than 3 adjacent levels.

Description:

The study involves a retrospective review of patients' medical records and prospective collection of X-rays, and patient outcome questionnaires.

The study population will include 100 consecutive lumbar interbody fusion and 100 consecutive cervical interbody fusion patients who meet the inclusion criteria and do not meet the exclusion criteria.

There will be 4 prospective study visits following consent. Follow-up will occur in accordance with standard of care practice and will continue to 12 months post-surgery

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: December 2025
• Est. primary completion date: September 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject was diagnosed with DDD, spinal stenosis, or spondylolisthesis;

2. Subject has undergone cervical or lumbar interbody spine fusion at no more than 3 adjacent levels between C2 and T1 or between L1 and S1;

3. Subject has undergone cervical or lumbar interbody spine fusion using NMP Fibers;

4. Subject must be 18 years of age or older at the time of consent;

5. Subject must be willing and able to sign an informed consent document;

6. Subject must be willing and able to return to the study clinic for all follow-up visits, agree to participate in post-operative clinical and radiographic evaluations.

Exclusion Criteria:

1. Subject is under 18 years of age at the time of consent;

2. Subject is currently experiencing major mental illness (psychosis, schizophrenia, major affective disorder) which in the opinion of the investigator may indicate that the symptoms are psychological rather than of physical origin;

3. Subject is currently imprisoned.

Related Conditions & MeSH terms

• Degenerative Disc Disease
• Degenerative Spondylolisthesis
• Intervertebral Disc Degeneration
• Spinal Stenosis
• Spondylolisthesis

Intervention

Biological:
• Natural Matrix Protein (NMP) Fibers
human bone allograft

Procedure:
• Lumbar interbody fusion
Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between L1 and S1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
• Cervical interbody fusion
Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between C2 and T1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.

Locations

Country	Name	City	State
United States	Southern Orthopedic Sports Medicine Associates	Jasper	Alabama

Sponsors (1)

Lead Sponsor	Collaborator
Induce Biologics USA Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of interbody fusion	Flexion and Extensions radiographs will be assessed for fusion at each level to be fused Fusion is defined as: (1) less than 5 degrees of motion by flexion extension X-ray and (2) no radiological features of non-union (radiolucency, implant migration, loss of graft height, supplemental fixation failure). Both fusion criteria have to be met to be considered a fusion success at the index level.	Baseline to 12 months post-operative
Primary	Incidence of secondary surgical intervention	Secondary surgical interventions (SSI) include revision, re-operation, removal, or supplemental fixation at the index levels	Baseline to 12 months post-operative
Primary	Incidence of Adverse Product Related Events	the incidence of the following will be reported: bone resorption with cage migration or subsidence, local inflammation with seromas, ectopic bone formation, radiculitis.	Baseline to 12 months post-operative
Secondary	Incidence of bridging bone	Plane radiographs will be evaluated for the presence of bridging bone at each level to be fused.	Baseline to 12 months post-operative
Secondary	Change in disability score for lumbar fusion patients assessed by Oswestry Disability Index	Disability will be assessed using the Oswestry Disability Index (ODI). ODI is a questionnaire to collect a patient's responses to questions about perceived function (disability) in 10 everyday activities in patients with acute or chronic low back pain. Each question consists of 6 statements about 1 activity which are scored from 0 to 5. With 0 indicating the least disability and 5 the greatest. The scores are combined to a single score from 0 (no disability) to 50 (completely disabled)	Baseline to 12 months post-operative
Secondary	Change in disability score for cervical fusion patients assessed by Neck Disability Index	Disability will be assessed using the Neck Disability Index (NDI). NDI is a questionnaire to collect a patient's responses to questions about perceived function (disability) in 10 everyday activities in patients with acute or chronic neck pain. Each question consists of 6 statements about 1 activity which are scored from 0 to 5. With 0 indicating the least disability and 5 the greatest. The scores are combined to a single score from 0 (no disability) to 50 (completely disabled)	Baseline to 12 months post-operative
Secondary	Change in back pain in lumbar fusion patients	Pain will be assessed by Visual Analogue Scale (VAS) for back pain. VAS is a straight horizontal line of fixed length. The ends are defined as the extreme limits of the pain to be measured from the left (no pain) to the right (worst pain imaginable) and the patient marks on the line how much pain they are experiencing at that time. The VAS score is determined by measuring in millimeters from the end of the line to the point that the patient marks. The minimum score is 0 and the maximum score is 100. The larger the number the worse the pain being experienced	Baseline to 12 months post-operative
Secondary	Change in leg pain in lumbar fusion patients	Pain will be assessed by Visual Analogue Scale (VAS) for back pain. VAS is a straight horizontal line of fixed length. The ends are defined as the extreme limits of the pain to be measured from the left (no pain) to the right (worst pain imaginable) and the patient marks on the line how much pain they are experiencing at that time. The VAS score is determined by measuring in millimeters from the end of the line to the point that the patient marks. The minimum score is 0 and the maximum score is 100. The larger the number the worse the pain being experienced.	Baseline to 12 months post-operative
Secondary	Change in neck pain in cervical fusion patients	Pain will be assessed by Visual Analogue Scale (VAS) for back pain. VAS is a straight horizontal line of fixed length. The ends are defined as the extreme limits of the pain to be measured from the left (no pain) to the right (worst pain imaginable) and the patient marks on the line how much pain they are experiencing at that time. The VAS score is determined by measuring in millimeters from the end of the line to the point that the patient marks. The minimum score is 0 and the maximum score is 100. The larger the number the worse the pain being experienced.	Baseline to 12 months post-operative
Secondary	Change in arm pain in cervical fusion patients	Pain will be assessed by Visual Analogue Scale (VAS) for back pain. VAS is a straight horizontal line of fixed length. The ends are defined as the extreme limits of the pain to be measured from the left (no pain) to the right (worst pain imaginable) and the patient marks on the line how much pain they are experiencing at that time. The VAS score is determined by measuring in millimeters from the end of the line to the point that the patient marks. The minimum score is 0 and the maximum score is 100. The larger the number the worse the pain being experienced.	Baseline to 12 months post-operative